Navigation Links
NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate
Date:10/15/2009

NCCN has added pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma. The FDA-approved pralatrexate for the treatment of peripheral T-cell lymphoma on September 25, 2009

FORT WASHINGTON, Pa., Oct. 15 /PRNewswire-USNewswire/ -- Upon the recent FDA approval of pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), the National Comprehensive Cancer Network (NCCN) has updated the NCCN Clinical Practice Guidelines in Oncology(TM) for Non-Hodgkin's Lymphomas to include pralatrexate as a suggested treatment regimen.

The updated NCCN Guidelines have added pralatrexate as a second-line therapy option for relapsed or refractory PTCL with a category 2A recommendation for patients who are not candidates for high dose therapy and a category 2B recommendation for patients who are candidates for high dose therapy.

Peripheral T-cell lymphoma is a rare form of non-Hodgkin's lymphoma that is particularly aggressive and challenging to treat. Pralatrexate recently became the first FDA-approved single agent therapy indicated for patients with relapsed or refractory disease, meaning those whose disease has returned or has not responded to other types of therapy.

NCCN Clinical Practice Guidelines in Oncology(TM) are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines are available free of charge at NCCN.org.

About the National Comprehensive Cancer Network

The Nationa
'/>"/>

SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. BioCryst Updates Peramivir Clinical Development Plan
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Mass. , Sept. 22, 2014  Seres Health, ... related to the human microbiome, today announced that it ... of 2014,s Fierce 15 biotechnology companies, designating it as ... the industry.  "Amid a great deal ... for its focus and commitment to practical therapeutic development," ...
(Date:9/22/2014)... PLEASANTON, Calif. , Sept. 22, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... D. Keith Grossman has been appointed President and ... F. Burbach , who has stepped down from his ... advisor to the company through the first quarter of ...
(Date:9/22/2014)... cancer is the second leading cause of cancer death ... early - the problem is that too often it ... Education Council (PCEC), – a national organization committed ... screening –  is sponsoring its 25 th Annual ... Committed to encouraging men to take a ...
Breaking Medicine Technology:Seres Health Named a "Fierce 15" Biotech Company for 2014 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3
... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... of the largest network of radiotherapy and diagnostic imaging ... directors approved a share repurchase program, effective immediately. ... States federal securities laws, Concord Medical is authorized to ...
... Sept. 29, 2011 The Educational Review System held ... 28 at the Meyedenbauer Center in Bellevue, WA. Attendees ... pharmacy thought leaders discuss the challenges of pediatric medications, ... the 2010 recipient of the Institute for Safe Medication ...
Cached Medicine Technology:Concord Medical Services Announces Share Repurchase Program 2Concord Medical Services Announces Share Repurchase Program 3
(Date:9/22/2014)... surprising new study pulls back the curtain on one ... in payment and income between physicians who perform operations, ... Contrary to perception, the research indicates, the physician payment ... other procedure-performing doctors. , The new findings counter the ... per minute explains why doctors who perform procedures often ...
(Date:9/22/2014)... Norton HealthDay Reporter MONDAY, ... better when newborn intensive care units (NICU) set up private ... new study finds. Researchers at one children,s hospital found ... less distressed when their NICU switched from the traditional "open-bay" ... online Sept. 22 in the journal Pediatrics , add ...
(Date:9/22/2014)... of patients undergoing breast cancer surgery require additional operations ... tissue in the initial operation. However, researchers at Brigham ... they developed that will help surgeons better distinguish cancerous ... for repeat operations. , The study ... in the Proceedings of the National Academy of ...
(Date:9/22/2014)... (September 22, 2014) McMaster scientists have found that ... class of antibiotics. , Although dozens of antibiotics ... how a certain part of bacteria are created, and ... , The discovery is important as there is ... the cures for infections ineffective. The World Health Organization ...
(Date:9/22/2014)... This Flash Report is a top-line view ... the Prostate Cancer market. , Download the flash report ... any launching Prostate Cancer product:, ... crowded market , Understanding stakeholder interactions with ... thought leaders and stakeholders ,Download the white paper ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:The fine line between breast cancer and normal tissues 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2
... engineer has developed a technique which uses plastidial transformation ... (HSA) from tobacco plants. HSA is an intravenous protein ... ,It is mainly used to stabilize blood ... is used for haemorrhages, burns, surgical operations or when ...
... Veterinary schools in sub-Saharan Africa have joined forces ... allow vets to study// for postgraduate degrees while ... Veterinary E-Learning Consortium, launched in early March, will ... full-time degrees, reported the SciDev.net science-for-development network. ...
... Conference (EBCC-5) have called that patients should have speedy access ... Doctors and patient groups said that women in Europe are ... could help prolong their survival and well being. ... are available to women in the United States far more ...
... Quest? cigarettes seems to have lulled smokers into a ... by researchers// at the Transdisciplinary Tobacco Use Research Center ... the study have been published in the journal Psychology ... study, Caryn Lerman, PhD, Associate Director for Cancer Control ...
... revealed that Africa's TB crisis has its origin in HIV/AIDS, ... two million people who die from TB every year, 1.5 ... the African Medical and Research Foundation (AMREF) clinic in the ... to TB were also infected with HIV. According to Nzioka, ...
... According to studies done at the Yale school of medicine, ... we get when we eat certain foodstuffs//, like garlic, mustard ... receptor they ay also underlines the reaction of the body ... vehicle exhaust and byproducts of certain chemo receptor drugs used ...
Cached Medicine News:Health News:Alternate ways to produce HAS from tobacco plants 2
For injecting viscoelastic to all meridians of the anterior chamber and to coat intraocular lenses. 20G x 7.8in (.90 x 22mm)....
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... is the most versatile diagnostic tool in ... solutions for glaucoma, diabetic retinopathy, age-related macular ... RTA is the only system in the ... pole and the optic nerve areas in ...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Medicine Products: